Lung Small Cell Carcinoma — Trials

Lung Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 381
Recruiting: 202
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (157)

clinicaltrialsPublishedShowing 1–14 of 14 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07802821	A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer	not yet recruiting	Phase 3	556	Qilu Pharmaceutical Co., Ltd.INDUSTRY	0	Sep 3, 2026	clinicaltrials
NCT07796100	A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer	not yet recruiting	Phase 3	530	Zai Lab (Shanghai) Co., Ltd.